Affinia Announces Indications For Gene Therapy Programs; Enters Manufacturing Agreement With Lonza

Affinia Therapeutics announced the first two indications it will pursue with the company's next-generation gene therapies: metachromatic leukodystrophy, a fatal neurodegenerative disease, and brain metastases secondary to human epidermal growth factor receptor 2 positive breast cancer, a deadly form of cancer. The therapeutic candidates for these two indications are based on proprietary capsid, Anc80L65.

Also, Affinia has entered into a multi-year deal with Lonza Group in which Lonza will provide contract development and manufacturing services to Affinia for initial product candidates.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Royal Caribbean Group's ultra-luxury brand Silversea Cruises is set to launch the world's first hybrid-powered cruise ship in the summer of 2023. This will also be the first ship with large-scale fuel cell technology to enable emission-free port operations. The fuel cells will provide 100% of power while at port. Affco USA is recalling around 24,461 pounds of frozen raw lamb shoulder products that were not presented for import re-inspection into the U.S., the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS announced. The recall involves the frozen raw lamb shoulder items that were imported on July 12, 2021. American Express Company (AXP) reported an increase in profit for the third quarter that also topped Wall Street estimates. Consolidated total revenues net of interest expense rose 25 percent year-on-year, primarily reflecting growth in Card Member spending, as well as a rise in the average discount...
Follow RTT